Liver Cancer Laboratory, Xiangya Hospital, Central South University, Changsha 410008, China.
Int J Biol Markers. 2013 Apr 23;28(1):71-83. doi: 10.5301/JBM.2013.10568.
To investigate the expression of Egfl7 in normal adult human tissues and human epithelial tumors.
RT-PCR and Western blot were employed to detect Egfl7 expression in normal adult human tissues and 10 human epithelial tumors including hepatocellular carcinoma (HCC), lung cancer, breast cancer, prostate cancer, colorectal cancer, gastric cancer, esophageal cancer, malignant glioma, ovarian cancer and renal cancer. Immunohistochemistry and cytoimmunofluorescence were subsequently used to determine the localization of Egfl7 in human epithelial tumor tissues and cell lines. ELISA was also carried out to examine the serum Egfl7 levels in cancer patients. In addition, correlations between Egfl7 expression and clinicopathological features as well as prognosis of HCC and breast cancer were also analyzed on the basis of immunohistochemistry results.
Egfl7 was differentially expressed in 19 adult human normal tissues and was overexpressed in all 10 human epithelial tumor tissues. The serum Egfl7 level was also significantly elevated in cancer patients. The increased Egfl7 expression in HCC correlated with vein invasion, absence of capsule formation, multiple tumor nodes and poor prognosis. Similarly, upregulation of Egfl7 in breast cancer correlated strongly with TNM stage, lymphatic metastasis, estrogen receptor positivity, Her2 positivity and poor prognosis.
Egfl7 is significantly upregulated in human epithelial tumor tissues, suggesting Egfl7 to be a potential biomarker for human epithelial tumors, especially HCC and breast cancer.
研究 Egfl7 在正常成人组织和人类上皮性肿瘤中的表达。
采用 RT-PCR 和 Western blot 检测 10 种人类上皮性肿瘤（包括肝癌、肺癌、乳腺癌、前列腺癌、结直肠癌、胃癌、食管癌、恶性胶质瘤、卵巢癌和肾癌）及 10 种人类上皮性肿瘤中 Egfl7 的表达。免疫组化和细胞免疫荧光检测 Egfl7 在人上皮性肿瘤组织和细胞系中的定位。酶联免疫吸附试验（ELISA）检测癌症患者血清 Egfl7 水平。此外，还根据免疫组化结果分析了 Egfl7 表达与肝癌和乳腺癌的临床病理特征及预后的相关性。
Egfl7 在 19 种成人正常组织中差异表达，在 10 种人类上皮性肿瘤组织中均过度表达。癌症患者的血清 Egfl7 水平也显著升高。肝癌中 Egfl7 的表达增加与静脉侵犯、无包膜形成、多个肿瘤结节和预后不良有关。同样，乳腺癌中 Egfl7 的上调与 TNM 分期、淋巴转移、雌激素受体阳性、Her2 阳性和预后不良密切相关。
Egfl7 在人类上皮性肿瘤组织中显著上调，提示 Egfl7 可能是人类上皮性肿瘤的潜在标志物，尤其是肝癌和乳腺癌。
